Welcome to the Instem Investor Centre

Globe

Instem (AIM:INS.L) is a leading provider of IT applications to the global early development healthcare market. The Group is focused on the early development sector of the drug and chemical research and development industry, from late discovery and lead optimisation through to the Phase I clinical evaluation stage.

Instem’s Early Development Applications (EDA’s) are used in evaluation studies to:

  • collect, analyse and report complex scientific data;
  • comply with regulatory reporting requirements;
  • improve quality, consistency and efficiency of information reporting; and
  • reduce the time of critical path R&D activities.

Instem’s solutions are supplied to an international blue chip customer base including AstraZeneca, GlaxoSmithKline and Charles River Laboratories.

Share price



Instem expects 2015 trading to be in line with expectations

Instem told investors it expected trading for the year to December 31 to be in line with market expe...

Instem CEO delivers corporate presentation

Phil Reason, the chief executive of Instem ( LON:INS ), provides an insight into the AIM-listed b...

UPDATE - Instem lands orders worth £1.4mln

---ADDS BROKER COMMENT AND SHARE PRICE--- Instem ( LON:INS ), which supplies software used by...

Instem has flying start to year as its drug compliance technology gains traction

The first two months of the year have seen an upturn in the stock market fortunes of Instem (LON:I...

Access New Research Note about FDA Mandate




Featured Video

Instem CEO most excited by FDA electronic submission business

Instem is a robust business, with net cash and a valuable customer base delivering high levels of recurring revenue. The business continues to increase its strong global market share and is well positioned to take advantage of the structural changes in the drug development industry. Both the regulatory and fiscal environments continue to be favourable to Instem, driving demand for all areas of our product suite.

The recent acquisitions of Logos Technologies and Perceptive Instruments mark important strategic moves into the early phase clinical and in vitro R&D marketplaces whilst providing additional cross-selling opportunities. Our clients now have the ability to turn to Instem as a global supplier for their data management needs across broader segments. We will continue to expand the Group's reach into complementary scientific domains as part of our growth strategy.

Phil Reason,
Chief Executive